论文部分内容阅读
日前,北京市药品监督管理局转发了国家中药品种保护审评委员会下发的《关于请及时办理〈国家中药保护品种审批件补充批件〉的函》,通知变更企业或药品名称的有关单位补充相关资料。 我国从1993年开始实施《中药品种保护条例》,到目前为止,共通过或正在审评各地申报的中药保护品种共计250余种。近年来,随着我国经济体制改革的深入发展,不少药品生产企业因改制、兼并或重组使企业名称发生了变更,这其中也涉及到相当一部分生产中药保护品种的企业。为加强中药保护品种的规范化管理,更好地维护中药保护品种生产企业的合法权益,国家中药品种
Recently, the Beijing Municipal Drug Administration has forwarded a letter issued by the National Committee for the Protection of Chinese Medicinal Plant Variety Protection on the timely processing of the “Supplementary Approval Document for the National Examination and Approval of Traditional Chinese Medicinal Products”, notifying the change of the name of the relevant company or drug company to supplement relevant data. China has implemented the Regulations on the Protection of Varieties of Chinese Medicinal Materials since 1993. So far, a total of more than 250 kinds of Chinese medicine protection varieties have been passed or are being reviewed. In recent years, with the in-depth development of China’s economic system reforms, many pharmaceutical manufacturing companies have changed the names of their companies due to restructuring, mergers, or reorganization. This also involves a considerable portion of enterprises producing traditional Chinese medicine protection varieties. In order to strengthen the standardized management of protected varieties of traditional Chinese medicine and better protect the legitimate rights and interests of traditional Chinese medicine protection breed production enterprises, the national varieties of Chinese medicine